Phase I Study of GC1008 (Fresolimumab): A Human Anti-Transforming Growth Factor-Beta (TGFβ) Monoclonal Antibody in Patients with Advanced Malignant Melanoma or Renal Cell Carcinoma - Concepedia

Concepedia

Publication | Open Access

Phase I Study of GC1008 (Fresolimumab): A Human Anti-Transforming Growth Factor-Beta (TGFβ) Monoclonal Antibody in Patients with Advanced Malignant Melanoma or Renal Cell Carcinoma

DOI Full Paper Access

474

Citations

37

References

2014

Year

John C. Morris, Antoinette R. Tan, Thomas Olencki, Geoffrey I. Shapiro, Bruce J. Dezube, Frank J. Hsu, Jay A. Berzofsky, Donald P. Lawrence

Abstract

Clinicaltrials.gov NCT00356460.

References

	Year	Citations

Page 1